Alliance for Pandemic Preparedness

June 25, 2020

Tocilizumab in Patients with Severe COVID-19: A Retrospective Cohort Study

Category:

Topic:

  • Tocilizumab treatment among patients with severe COVID-19, whether administered intravenously or subcutaneously, was associated with a reduced risk of invasive mechanical ventilation or death (adjusted HR = 0.61, 95% CI: 0.40-0.92) in a retrospective study (n=544). However, a significantly larger proportion of tocilizumab recipients were diagnosed with new infections compared with patients treated with standard of care (13% vs 4%, p < 0.0001). 

Guaraldi et al. (June 24, 2020). Tocilizumab in Patients with Severe COVID-19: A Retrospective Cohort Study. The Lancet Rheumatology. https://doi.org/10.1016/S2665-9913(20)30173-9